Emergent BioSolutions, Inc. (NYSE:EBS)
A biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics. The Company operates in two business segments: biodefense and commercial.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
EnigmaDude
(98.87)
Submitted: 10/3/2011 4:51:08 PM :
Start Price:
$16.89
EBS Score:
-21.28
Emergent BioSolutions receives award to supply 44.75 mln doses of BioThrax to U.S. Government over 5 Years for a total value of up to $1.25 bln
Recs
zzlangerhans
(99.26)
Submitted: 7/30/2011 12:50:39 AM :
Start Price:
$20.51
EBS Score:
-19.08
The stock has bounced upward from these levels twice already this year. The company claims that a dramatic drop in Biothrax revenues last quarter was due to an "internal process of redeployment" that has now been substantially completed. No, I don't know what that means. But they projected record revenues of 80-90M for the current quarter and total 2011 revenues of 320-340M, with net income of 35-45M. The next earnings will be reported on August 4 and if the company is true to their word, the share price will surely gap up. If they're surprised and disappointed, who knows.
Meanwhile the company has numerous other dishes in the kitchen. They recently initiated a phase Ib trial of cheaply acquired Trubion compound TRU-16 in relapsed B cell lymphoma. Trubion's SBI-087 is in a phase II dose finding study for rheumatoid arthritis. Data from a phase II trial of their TB vaccine in infants is expected in H2 2012, and a phase IIb trial of the TB vaccine in HIV patients may be initiated in the near future. The company has also acquired rights to zanolimumab anti-T cell antibody for CTCL and PTCL from TenX Biopharma.
Recs
TrojanFan
(79.11)
Submitted: 7/7/2011 4:13:41 PM :
Start Price:
$21.89
EBS Score:
-21.14
Recent approval of Biothraxx by Singapore HSA is a promising development as the company tries to expand its marketing reach into other places such as Brunei.
I'm a little nervous about the impact of the debt ceiling debate and the potential for delayed or reduced purchases by the US govt, but given the homeland security angle that should offer them some protection.
I'm looking for good earnings for last quarter because their press releases indicate that they shipped a LOT of product this quarter.
Recs
Lippoldtskivich
(58.40)
Submitted: 6/29/2011 11:45:22 AM :
Start Price:
$22.47
EBS Score:
-25.64
Portfolio of medical products relevant to health and security issues, with potential to grow. Volatile though, so buy on dips.
Recs
RallyCry
(< 20)
Submitted: 5/17/2011 10:33:23 PM :
Start Price:
$22.12
EBS Score:
-22.41
Current Parameters
Rev. Growth Rate (last 3 Yrs)
5.00 - 3430.50
EPS Growth Rate (last 3 Yrs)
5.00 - 1121.10
Industry
Drugs
Active Picks
0.00 - 25889.00
CAPS Rating
5 - 5 on 2011-05-16
Recs
NicolasDarvas
(< 20)
Submitted: 1/6/2011 6:56:16 PM :
Start Price:
$23.67
EBS Score:
-32.03
Test, 2011.
Recs
Recs
Clint35
(68.90)
Submitted: 4/5/2010 9:19:19 PM :
Start Price:
$16.67
EBS Score:
-9.38
A cheap biotech with 5 stars.
Recs
whirlyfish
(< 20)
Submitted: 2/17/2010 11:23:38 AM :
Start Price:
$14.79
EBS Score:
-4.97
TB and Chlamydia vaccines. As well as upcoming antgrax demand.
Recs
blackmonday2007
(< 20)
Submitted: 9/15/2009 11:52:59 AM :
Start Price:
$19.59
EBS Score:
-39.43
MIKE TURNER PICK
Recs
cayamax
(32.41)
Submitted: 9/11/2009 11:09:20 AM :
Start Price:
$19.27
EBS Score:
-38.33
Sadly, bioterrorism and biowarfare will be a threat for quite awhile.
Recs
dantefromsomm
(< 20)
Submitted: 9/3/2009 11:50:30 PM :
Start Price:
$17.54
EBS Score:
-34.94
Very high insider ownership with alot of potential for blow ups with product develope ments.Same basic formula i like.Increasing balance sheets, reasonably low p/e,good insider ownership,low debt.
Recs
Ulenspiegel101
(< 20)
Submitted: 6/2/2009 3:07:11 PM :
Start Price:
$11.89
EBS Score:
+3.27
proven innovator
Recs
Tyrone85
(79.82)
Submitted: 2/19/2009 9:57:09 PM :
Start Price:
$21.02
EBS Score:
-95.72
after/ 1st q of 2009
Recs
fivehaus
(79.47)
Submitted: 2/19/2009 9:56:35 AM :
Start Price:
$22.59
EBS Score:
-94.46
Daily, weekly. monthly trends are up. Increasing sales, increasing earnings. a good sales base with the U.S. Military.
Recs
cjstock02
(< 20)
Submitted: 1/28/2009 2:59:20 PM :
Start Price:
$21.11
EBS Score:
+74.10
We developed a gap down after a long run up. That looks very bearish on the chart.
Recs
sprucemoose2
(52.49)
Submitted: 1/5/2009 2:27:31 PM :
Start Price:
$26.07
EBS Score:
-80.77
has a constant revenue stream from the good ole US of A and sticks to its 50 day MA very well
Recs
viasyncro
(< 20)
Submitted: 12/20/2008 12:34:07 PM :
Start Price:
$25.97
EBS Score:
-87.55
Niche company with growing market share
Recs
MalibuGuru
(78.67)
Submitted: 12/9/2008 5:08:54 PM :
Start Price:
$24.40
EBS Score:
-81.48
Emergent BioSolutions maintains a large economic moat through it's Biothrax vaccine. Two of it's vaccines in late stage development, a typhoid vaccine candidate and a hepatitis B therapeutic vaccine candidate, uniquely positions EBS to take advantage of the expected huge growth of demand in LDC and MDC.
Recs
DNAdivaSTL
(43.41)
Submitted: 12/2/2008 4:18:53 PM :
Start Price:
$13.48
EBS Score:
+21.84
When your biggest customer is Big Brother, growth is inevitable....
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 49 : 1 2 3 Next »